Patents Assigned to Stichting Katholieke Universiteit, The University Medical Centre Nijmegen
-
Publication number: 20200392588Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: August 24, 2020Publication date: December 17, 2020Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 9951390Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: GrantFiled: April 13, 2016Date of Patent: April 24, 2018Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 9540696Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.Type: GrantFiled: September 23, 2013Date of Patent: January 10, 2017Assignees: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, The Johns Hopkins UniversityInventors: Marion J. G. Bussemakers, William B. Isaacs
-
Publication number: 20150307948Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: June 22, 2015Publication date: October 29, 2015Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Patent number: 9096907Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: GrantFiled: June 10, 2013Date of Patent: August 4, 2015Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, J. Alfred Witjes
-
Publication number: 20130261171Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: ApplicationFiled: June 10, 2013Publication date: October 3, 2013Applicant: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, Alfred J. Witjes
-
Patent number: 8257924Abstract: Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described.Type: GrantFiled: May 5, 2011Date of Patent: September 4, 2012Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, Alfred J. Witjes
-
Patent number: 7960109Abstract: Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.Type: GrantFiled: December 23, 2005Date of Patent: June 14, 2011Assignee: Stichting Katholieke Universiteit, The University Medical Centre NijmegenInventors: Daphne Hessels, Gerald Verhaegh, Jack A. Schalken, Alfred J. Witjes